Brief: Isofol Initiates Preclinical Evaluation Of Arfolitixorin With Oncosyne AS
April 28 (Reuters) - Isofol Medical AB (publ) ISOFOL.ST :
* INITIATES PRECLINICAL EVALUATION OF ARFOLITIXORIN WITH ONCOSYNE AS
* AIMS TO EVALUATE SEVERAL DOSES OF ARFOLITIXORIN IN COMBINATION WITH 5-FU AS WELL AS OTHER
POSSIBLE TREATMENTS WITHIN RESEARCH COLLABORATION WITH NORWEGIAN
BIOTECH COMPANY oNCOSYNE
Source text for Eikon: ID:nWkrlf2YD
Further company coverage: ISOFOL.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Isofol Medical AB (publ)
See all newsSweden's Isofol Medical Q1 net loss widens, raises funds
Brief: Isofol Medical Q1 Net Income SEK -15.062 Million
Brief: Isofol Medical Announces Bfarm Approval Of Optimized Phase Ib/Ii Study Design
Brief: Isofol Gets Gross Proceeds Of SEK 18.9 Mln In Connection With Exercise Of Warrants And Guarantee Commitments
Brief: Isofol Secures License Rights For Arfolitixorin In Autism